Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
British Journal of Haematology · 2026-02 · 208 (2) · 752-757
DOI: 10.1111/bjh.70248 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 12.11.2025. Verfasst von Elisabetta Petracci und 26 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute, Ricerca Corrente, Ministero della Salute.
Abstract (Originalsprache)
follow-up is needed to better define the durability of responses and late toxicity. In conclusion, despite the high NRM, our data confirm the utility of HMA-VEN as an effective bridge to allo-HSCT in REF/REL AML, because it brings an advantage in terms of relapse, especially considering that approximately 30% of patients in our cohort were not in CR/CRi at the time of allo-HSCT. Furthermore, 38.9% of patients alive and disease-free at last follow-up have an expected good quality of life, as demonstrated by the GRFS of 44%. These findings support the broader implementation of HMA-VEN in this setting, especially for patients traditionally considered ineligible for intensive salvage therapy. Future trials comparing HMA-VEN to intensive chemotherapy as a pretransplant regimen, and studies incorporating matched related donor monitoring and maintenance strategies post-transplant are warranted to further optimize outcomes in this high-risk group.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
- Hematology Unit, ASST Valle Olona Hospital, Busto Arsizio, Italy.
- BMT Unit, AOR 'Villa Sofia-Cervello', Palermo, Italy.
- Oncohematology Department, Fondazione IRCCS Policlinico 'San Matteo', Pavia, Italy.
- IRCCS AOU di Bologna, 'L. e A. Seràgnoli' Hematology Institute, Bologna, Italy.
- Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University, Bolzano, Italy.
ORCID-Profile: Calogero Vetro, Giovanni Marconi
Förderung
- Ministero della Salute, Ricerca Corrente
- Ministero della Salute
Zitieren
APA
Petracci, E., Pavesi, F., Castagna, L., Zappasodi, P., Papayannidis, C., Vetro, C., Federico, V., Cignetti, A., Borlenghi, E., Fracchiolla, N., Facchini, L., Maurillo, L., Audisio, E., Bernardi, M., Ferrara, F., Lanza, F., Selleri, C., Manfra, I., Cerchione, C., …, & Todisco, E. (2026). Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study. British Journal of Haematology, 208(2), 752-757. https://doi.org/10.1111/bjh.70248
Vancouver
Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, et al. Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study. British Journal of Haematology. 2026;208(2):752-757. doi:10.1111/bjh.70248
BibTeX
@article{Petracci2026,
author = {Petracci, Elisabetta and Pavesi, Francesca and Castagna, Luca and Zappasodi, Patrizia and Papayannidis, Cristina and Vetro, Calogero and Federico, Vincenzo and Cignetti, Alessandro and Borlenghi, Erika and Fracchiolla, Nicola and Facchini, Luca and Maurillo, Luca and Audisio, Ernesta and Bernardi, Massimo and Ferrara, Felicetto and Lanza, Francesco and Selleri, Carmine and Manfra, Ilenia and Cerchione, Claudio and Nanni, Jacopo and Romagnoli, Andrea Davide and Marconi, Giovanni and Zingaretti, Chiara and Lotesoriere, Ivana and Gigli, Federica and Martinelli, Giovanni and Todisco, Elisabetta},
title = {Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {2},
pages = {752--757},
doi = {10.1111/bjh.70248}
}
EUVIMED